Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

The Relationship between MDR1 Polymorphisms and the Response to Etoposide/Cisplatin Combination Chemotherapy in Small Cell Lung Cancer

소세포폐암에서 Multidrug Resistance-1 유전자의 다형성과 Etoposide-cisplatin 항암화학요법 반응의 관계

  • Sohn, Ji Woong (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Lee, Shin Yup (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Lee, Su Jung (Cancer Research Center, Kyungpook National University) ;
  • Jeon, Hyo-Sung (Cancer Research Center, Kyungpook National University) ;
  • Lee, Jae Hee (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Park, Jae Hyung (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Kim, Eun Jin (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Kang, Young Mo (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, School of Medicine, Kyungpook National University) ;
  • Cha, Seung Ick (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Kim, Chang Ho (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Jung, Tae Hoon (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Park, Jae Yong (Department of Internal Medicine, School of Medicine, Kyungpook National University)
  • 손지웅 (경북대학교 의과대학 내과학교실) ;
  • 이신엽 (경북대학교 의과대학 내과학교실) ;
  • 이수정 (경북대학병원 암연구센터) ;
  • 전효성 (경북대학병원 암연구센터) ;
  • 이재희 (경북대학교 의과대학 내과학교실) ;
  • 박재형 (경북대학교 의과대학 내과학교실) ;
  • 김은진 (경북대학교 의과대학 내과학교실) ;
  • 강영모 (경북대학교 의과대학 내과학교실) ;
  • 이재태 (경북대학교 의과대학 핵의학교실) ;
  • 차승익 (경북대학교 의과대학 내과학교실) ;
  • 김창호 (경북대학교 의과대학 내과학교실) ;
  • 정태훈 (경북대학교 의과대학 내과학교실) ;
  • 박재용 (경북대학교 의과대학 내과학교실)
  • Received : 2004.12.20
  • Accepted : 2005.01.18
  • Published : 2005.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

배경 및 목적 : Multidrug Resistance-1 (MDR1) 유전자는 다약제내성에 관여하는 P-glycoprotein을 암호화한다. MDR1 유전자의 다형성은 P-glycoprotein의 발현과 기능의 차이를 일으켜 항암화학요법 반응에 영향을 미칠 수 있을 것이다. 저자들은 소세포폐암 환자에서 MDR1 유전자의 다형성과 일배체형에 따른 항암화학요법에 대한 반응을 조사하였다. 대상 및 방법 : 경북대학병원에서 병리적으로 소세포폐암으로 진단받고 etoposide-cisplatin 항암화학요법을 받은 54명을 대상으로 하였다. 전혈 5cc에서 DNA를 추출하고 PCR-RFLP법을 통해 MDR1 유전자 엑손 21의 2677G>T 다형성과, 엑손 26의 3435C>T 다형성을 조사하고 다형성과 일배체형에 따른 항암화학요법의 반응을 조사하였다. 결 과 : 2677G>T 유전자형에 따른 항암화학요법의 반응은 유의한 차이가 없었다. 3435 CC 유전자형은 3435 CT+TT 형에 비해 치료 반응율이 유의하게 높았다 (P = 0.025). 유전자형 분석 결과와 일치되게 2677G/3435C 일배체형은 다른 일배체형에 비해 치료반응을 보이는 경우가 유의하게 많았다 (P = 0.015). 결 론 : 소세포폐암에서 MDR1 유전자의 2677G>T와 3435C>T 다형성 및 이들 다형성의 일배체형은 etoposide-cisplatin 항암화학요법의 반응을 예측할 수 있는 지표로 사용될 수 있을 것으로 생각된다.

Keywords

References

  1. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest 1997;112:251S-8S https://doi.org/10.1378/chest.112.1.251
  2. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123:259S-71S https://doi.org/10.1378/chest.123.1_suppl.259S
  3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58 https://doi.org/10.1038/nrc706
  4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9 https://doi.org/10.1016/0092-8674(86)90595-7
  5. Dean M, Rzhetsky A, Allikmets R. The human ATPbinding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66 https://doi.org/10.1101/gr.GR-1649R
  6. Stouch TR, Gudmundsson O. Progress in under. standing the structure-activity relationships of Pglycoprotein. Adv Drug Deliv Rev 2002;54:315-28 https://doi.org/10.1016/S0169-409X(02)00006-6
  7. Holzmayer TA, Hilsenbeck S, von Hoff DD, Raninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992;84:1486-91 https://doi.org/10.1093/jnci/84.19.1486
  8. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, Hanania N, et al. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 1993;85:2023-9 https://doi.org/10.1093/jnci/85.24.2023
  9. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997;3:115-22
  10. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 1998; 34:1352-7 https://doi.org/10.1016/S0959-8049(98)00067-7
  11. Hsia TC, Lin CC, Wang JJ, Ho ST, Kao A. Re. lationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002;180: 173-9 https://doi.org/10.1007/s004080000091
  12. Lutterbach B, Sun D, Schuetz J, Hiebert SW. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 pro. moter by the t(8;21) fusion protein. Mol Cell Biol 1998;18:3604-11 https://doi.org/10.1128/MCB.18.6.3604
  13. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima H, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998;92:4296-307
  14. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 1997;99:1947- 57 https://doi.org/10.1172/JCI119362
  15. Marzolini C, Paus E, Buclin T, Kim RB. Polymor. phisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33 https://doi.org/10.1016/j.clpt.2003.09.012
  16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymor. phisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8
  17. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-99 https://doi.org/10.1067/mcp.2001.117412
  18. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-310 https://doi.org/10.1016/S0169-409X(02)00064-9
  19. World Health Organization. WHO handbook for reporting results of cancer treatment, WHO offset publication no. 48. Geneva: World Health Organization; 1979
  20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89 https://doi.org/10.1086/319501
  21. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian po. pulations. Pharmacogenetics 2002;12:437-50 https://doi.org/10.1097/00008571-200208000-00004
  22. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481-94 https://doi.org/10.1097/00008571-200308000-00006
  23. Park SH, Lee GY, Jeon HS, Lee SJ, Kim KM, Jang SS, et al. -93G$\rightarrow$A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 2004;112: 678-82 https://doi.org/10.1002/ijc.20359
  24. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002;72:584-94 https://doi.org/10.1067/mcp.2002.129196
  25. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54:610-6 https://doi.org/10.1046/j.1365-2125.2002.01691.x
  26. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71:297-303 https://doi.org/10.1067/mcp.2002.122055
  27. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-62
  28. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43
  29. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1(C3435T) poly. morphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-54 https://doi.org/10.1097/01.ASN.0000019412.87412.BC
  30. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the Pglycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003;13:259-63 https://doi.org/10.1097/00008571-200305000-00004